Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response

Journal of Clinical Gastroenterology

Volumn 45, Issue 2, 2011, Pages 113-118

  Chaparro, María ^a,b   Panes, Julián ^b,c   García, Valle ^c   Mañosa, Miriam ^d   Esteve, María ^e   Merino, Olga ^e   Andreu, Montserrat ^f   Gutierrez, Ana ^g   Gomollón, Fernando ^h   Cabriada, José Luis ^e   Montoro, Miguel Angel ^e   Mendoza, Juan Luis ^e   Nos, Pilar ^e   Gisbert, Javier P ⁱ  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Clinical Center   (Spain)

^c Infectious Diseases Section   (Spain)

^d H Germans Trias i Pujol   (Spain)

^e Hospital Del Mar ^*

^f HOSPITAL DEL MAR   (Spain)

^g General de Alicante   (Spain)

^h Hospital Clinieo Universitario Lozano Blesa   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Crohn's disease; dose escalation; Infliximab; intensification; loss of response

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE;

ADULT; CIGARETTE SMOKING; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PSORIASIS; REMISSION; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

EID: 78951478130     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181ebaef9     Document Type: Review

References (31)

1. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther. 2006;23:451-463.
2. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
3. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007;133:312-339.
4. Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohns disease. Inflamm Bowel Dis. 2007;13:1093-1099.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet. 2002;359:1541-1549.
6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004;350:876-885.
7. Panes J, Gomollon F, Taxonera C, et al. Crohns disease: a review of current treatment with a focus on biologics. Drugs. 2007;67:2511-2537.
8. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohns disease: a review. Am J Gastroenterol. 2009;104:760-767.
9. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med. 1999;340:1398-1405.
10. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
11. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohns disease. Gastroenterology. 1999;117:761-769.
12. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med. 2003;348:601-608.
14. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
15. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohns disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
16. Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohns disease treatment with infliximab. Dig Dis Sci. 2008;53:1033-1041.
17. Corman S, Issa M, Beaulieu DB, et al. Escalation of infliximab maintenance therapy in Crohns disease. Am J Gastroenterol. 2006;101:S470.
18. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohns disease. Aliment Pharmacol Ther. 2003;17:1451-1457.
19. Luna-Chadid M, Perez Calle JL, Mendoza JL, et al. Predictors of response to infliximab in patients with fistulizing Crohns disease. Rev Esp Enferm Dig. 2004;96:379-381; 382-384.
20. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohns disease. Am J Gastroenterol. 2000;95:3490-3497.
21. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohns disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275.
22. Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohns disease. Eur J Gastroenterol Hepatol. 1996;8:225-228.
23. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohns disease. Gastroenterology. 1996;110:424-431.
24. Thomas GA, Rhodes J, Green JT. Inflammatory bowel disease and smoking - a review. Am J Gastroenterol. 1998;93:144-149.
25. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohns disease. Gastroenterology. 2002;123:707-713.
26. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohns disease. Am J Gastroenterol. 2002;97:2357-2363.
27. Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohns disease. Inflamm Bowel Dis. 2004;10:346-351.
28. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease. Gastroenterology. 2004;126:402-413.
29. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation versus initiation of adalimumab for loss of response in Crohns disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520.
30. Seksik P, Nion-Larmurier I, Sokol H, et al. Effects of light smoking consumption on the clinical course of Crohns disease. Inflamm Bowel Dis. 2009;15:734-741.
31. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohns disease. Clin Immunol. 2006;118:11-19.